The majority of bladder cancer is non-muscle invasive and is often associated with favorable prognosis.1,2 However, high-grade NMIBC is associated with an increased risk of recurrence and progression.3
Of the approximately 80,000 new cases of bladder cancer in the United States every year, approximately 10% will present with high-grade NMIBC.4,5
Intravesical bacillus Calmette-Guérin (BCG) is the standard of care for first-line treatment of high-grade NMIBC.1,2 However, high rates of BCG failure highlight the need for additional therapies.3,6
UGN-201 is an investigational local immunotherapy for the treatment of high-grade NMIBC bladder cancer. It is a proprietary formulation of imiquimod, a toll-like receptor 7/8 (TLR7/8) agonist, that is known to elicit an immune response to bladder cancer.